Industry
Biotechnology
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 7:21 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 1:09 pm
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 2:22 pm
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 11:07 am
Portfolio Pulse from Benzinga Newsdesk
July 23, 2024 | 12:09 pm
Portfolio Pulse from Benzinga Newsdesk
July 16, 2024 | 3:02 pm
Portfolio Pulse from Benzinga Newsdesk
June 28, 2024 | 11:47 am
Portfolio Pulse from Benzinga Newsdesk
June 11, 2024 | 6:53 pm
Portfolio Pulse from Benzinga Newsdesk
June 11, 2024 | 6:38 pm
Portfolio Pulse from Benzinga Newsdesk
June 06, 2024 | 12:02 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.